Theorem Clinical Research

R&D Trends

Roche, Meiji and Fedora partner to explore bacterial resistance to antibiotics

Wednesday, January 14, 2015 12:38 PM

RocheMeiji Seika Pharma and Fedora have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development. Meiji Seika Pharma is a Japan-based maker of antibacterial drugs. Fedora Pharmaceuticals is headquartered in Edmonton, Alberta, Canada.

More... »

Quest Diagnostics

Vedanta Biosciences inks agreement with Janssen, Johnson & Johnson Innovation

Wednesday, January 14, 2015 12:29 PM

Vedanta Biosciences, a Boston-based microbiome company, has announced a license agreement with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for Vedanta's lead microbiome pharmaceutical candidate (VE202), which has demonstrated efficacy in published preclinical studies using models of autoimmune disease. The agreement was facilitated by the Johnson & Johnson Innovation Center in Boston.

More... »

Eli Lilly inks agreements with Merck, Bristol-Myers Squibb

Wednesday, January 14, 2015 12:21 PM

Eli Lilly has formed two separate collaboration agreements. The first agreement with Merck is an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials. The second, with Bristol-Myers Squibb, is a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of BMS' immunotherapy Opdivo (nivolumab) in combination with Lilly's galunisertib (LY2157299).

More... »

Alnylam, Isis extend decade-long partnership for RNA therapeutics

Tuesday, January 13, 2015 09:00 AM

Isis Pharmaceuticals, based in Carlsbad, Calif., and Alnylam Pharmaceuticals, based in Cambridge, Mass., have formed a new agreement, extending their existing strategic partnership—formed originally in 2004—to lead the development and commercialization of RNA therapeutics.

More... »

Incyte, Agenus ink global alliance to develop novel immuno-oncology antibodies

Monday, January 12, 2015 02:42 PM

Incyte, a Wilmington, Del.-based biopharmaceutical company, and Agenus, an immuno-oncology company based in Lexington, Mass., have formed a global license, development and commercialization agreement focused on novel immuno-therapeutics using Agenus' proprietary Retrocyte Display antibody discovery platform.

More... »

X-Chem collaborates with Janssen and Johnson & Johnson Innovation

Monday, January 12, 2015 02:40 PM

X-Chem, a privately held biotechnology company based in Waltham, Mass., applying its drug discovery platform to the generation of novel small molecule therapeutics, has announced a multi-target collaboration with Janssen Biotech, one of the Janssen Pharmaceutical Companies of Johnson & Johnson.  The collaboration, which is being facilitated by Johnson & Johnson Innovation, Boston, focuses on the discovery and development of candidate molecules for the treatment of inflammatory diseases.

More... »

Report: Sponsors will boost productivity, control R&D costs in 2015

Friday, January 9, 2015 01:54 PM

Drug developers will implement strategies over the next year to improve clinical study performance to help control R&D costs and boost overall productivity, while increasing their focus on the development of cost-effective therapies that can help lower healthcare spending, according to the Tufts Center for the Study of Drug Development (CSDD).

More... »

Tetragenetics, MedImmune collaborate on ion channel drug discovery program

Thursday, January 8, 2015 01:03 PM

Tetragenetics, an emerging biotechnology company based in Cambridge, Mass., will collaborate with MedImmune, the global biologics R&D arm of AstraZeneca, on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune's antibody drug discovery programs.

More... »

23andMe, Genentech partner to analyze genomic data for Parkinson’s

Thursday, January 8, 2015 01:00 PM

23andMe, a privately held personal genomics and biotechnology company based in Mountain View, Calif., has inked an agreement with Genentech, a member of the Roche Group, to generate whole genome sequencing data for approximately 3,000 people in 23andMe’s Parkinson’s disease community. The goal of the collaboration is to identify new therapeutic targets for treating Parkinson’s disease.

More... »

Isis Pharmaceuticals, Janssen collaborate

Wednesday, January 7, 2015 12:59 PM

Isis Pharmaceuticals, based in Carlsbad, Calif., has entered into a global collaboration with Janssen Biotech to discover and develop antisense drugs to treat autoimmune disorders of the gastrointestinal (GI) tract. The collaboration brings together Isis' RNA-targeted technology platform and the expertise of Janssen in autoimmune disorders and therapeutic formulation to discover and develop antisense drugs that can be locally administered, including oral delivery, to treat autoimmune disorders in the GI tract.

More... »


March 2

Huntingdon Life Sciences-Harlan prepares for rebranding and U.S. expansion to compete with early phase CROs Covance, CRL

Patients' increased sharing of clinical trial experiences through social media can help sponsors improve outcomes, enrollment

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly


Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly


Study grants market breaks $13 billion
Volume of clinical activity rising while growth in grant spending slows

Revisiting eClinical Technology Solutions Adoption
While use of established solutions grows, sponsors hesitate on newer tools

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.


Featured Jobs